<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4745">
  <stage>Registered</stage>
  <submitdate>6/11/2014</submitdate>
  <approvaldate>6/11/2014</approvaldate>
  <nctid>NCT02316717</nctid>
  <trial_identification>
    <studytitle>A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis</studytitle>
    <scientifictitle>A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IMM-124E-2001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-alcoholic Steatohepatitis (NASH)</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - IMM-124E
Other interventions - Placebo

Experimental: Treatment Arm A - IMM-124E, 600 mg three times daily, orally plus matching placebo

Experimental: Treatment Arm B - IMM-124E, 1200 mg three times daily, orally

Placebo Comparator: Treatment Arm C - Matching placebo, three times daily, orally


Other interventions: IMM-124E
IMM-124E

Other interventions: Placebo
Matched placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Body Temperature - Changes in body temperature</outcome>
      <timepoint>24 Weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage Fat Content of the Liver - Mean change from Baseline in Percentage Fat Content of the Liver measured by Magnetic Resonance Imaging (MRI) at Week 24</outcome>
      <timepoint>24 Weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Adverse Events - Number of patients with adverse events</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Adverse Events - Severity of adverse events</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Respiratory Rate - Change in Respiratory Rate</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pulse Rate - Change in Pulse Rate</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Systolic Blood Pressure - Change in Systolic Blood Pressure</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Diastolic Blood Pressure - Change in Diastolic Blood Pressure</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Hematology, Coagulation, Clinical Chemistry, Serum Lipids, Blood Glucose and Urinalysis - Change in Clinical Laboratory tests (Hematology, Coagulation, Clinical Chemistry, Serum Lipids, Blood Glucose and Urinalysis)</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Serum Alanine Aminotransaminase (ALT) - Mean change from Baseline in Serum Alanine Aminotransaminase (ALT) at Week 24</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Peak serum concentration (Cmax) - Peak serum concentration (Cmax) of IMM-124E</outcome>
      <timepoint>0, 4, 12 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minimum serum concentration (Cmin) - Minimum serum concentration (Cmin) of IMM-124E</outcome>
      <timepoint>0, 4, 12 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area Under the Concentration Time Curve (AUC) - Area Under the Concentration Time Curve (AUC) of IMM-124E</outcome>
      <timepoint>0, 4, 12 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Elimination Half Life (T1/2) - Elimination Half Life (T1/2) of IMM-124E</outcome>
      <timepoint>0, 4, 12 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body Mass Index (BMI) - Change from Baseline of Body Mass Index (BMI) at 24 weeks</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Waist Circumference - Change from Baseline of Waist Circumference at 24 weeks</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Waist:Hip Ratio - Change from Baseline of Waist:Hip Ratio at 24 weeks</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hemoglobin (HB)A1C - Change from Baseline of Hemoglobin(HB)A1C at 24 weeks</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) - Change from Baseline of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at 24 weeks</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Cholesterol - Change from Baseline of Total Cholesterol at 24 weeks</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Triglycerides - Change from Baseline of Triglycerides at 24 weeks</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Low density lipoprotein (LDL) - Change from Baseline of Low Density Lipoprotein (LDL) at 24 weeks</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>High Density Lipoprotein (HDL) - Change from Baseline of High Density Lipoprotein (HDL) at 24 weeks</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum Alanine Aminotransaminase (ALT) - Mean change from Baseline of serum ALT</outcome>
      <timepoint>0, 4, 8, 12, 16, 20 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum Aspartate Aminotransaminase (AST) - Mean change from Baseline of Serum AST</outcome>
      <timepoint>0, 4, 8, 12, 16, 20 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bilirubin - Mean change from Baseline of Bilirubin</outcome>
      <timepoint>0, 4, 8, 12, 16, 20 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Albumin - Mean change from Baseline of Albumin</outcome>
      <timepoint>0, 4, 8, 12, 16, 20 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gamma Glutamyl Transpeptidase (GGT) - Mean change from Baseline of Gamma Glutamyl Transpeptidase (GGT)</outcome>
      <timepoint>0, 4, 8, 12, 16, 20 and 24 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum Alanine Aminotransaminase (ALT) - Number of patients with ALT within the normal reference range at Week 24(defined a &lt;19 IU/L for women and &lt;30 IU/L for men)</outcome>
      <timepoint>24 Weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age = 18 years.

          2. Provision of written informed consent.

          3. Diagnosis of NASH, histologically proven within 12 months of Screening with

               -  NASH activity score (NAS) of 4 or more

               -  cytologic ballooning score of at least 1;

               -  10% or more macrovescicular steatosis.

               -  Hematoxylin &amp; Eosin (H&amp;E) stained slides and/or paraffin block available for
                  independent assessment.

          4. HBA1C of &lt;9.0

          5. Agree to the use of effective contraceptive measures if either male or female of child
             bearing potential.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Presence of vascular liver disease or cirrhosis;

          2. Presence of liver disease with other cause (autoimmune, metabolic, medication
             induced);

          3. BMI &lt;25 kg/m^2;

          4. Alcohol use &gt;30 g/day;

          5. Type 1 diabetes;

          6. 6. History of major bariatric surgery (not including balloon / sleeve gastrectomy);

          7. Weight loss or gain of 5kg or more in the past 6 months or &gt;10% change in bodyweight
             in the past 12 months;

          8. Contraindication for MRI;

          9. Inadequate venous access;

         10. Lactating/breastfeeding/pregnant at Screening or Baseline;

         11. HIV antibody positive, hepatitis B surface antigen positive (HBsAg) or Hepatitis C
             virus (HCV)-RNA positive;

         12. Receiving an elemental diet or parenteral nutrition;

         13. Concurrent conditions

               -  Inflammatory bowel disease;

               -  Unstable angina, myocardial infarction, transient ischemic events, or stroke
                  within 24 weeks of Screening;

               -  Ongoing infectious, ongoing multi-systemic immune-mediated and/or concurrent or
                  past malignant disease;

               -  Any other concurrent condition which, in the opinion of the investigator, could
                  impact adversely on the subject participating or on the interpretation of the
                  study data;

         14. Concurrent medications including:

               -  anti-NASH therapy(s) taken for more than 10 continuous days in the last 3 months.
                  These include S-adenosyl methionine (SAM-e), betaine, milk thistle, probiotic
                  supplements (other than yoghurt), vitamin E and gemfibrozil.

                    -  NB: If vitamin E or gemfibrozil are used, the dose must be stable and liver
                       biopsy confirming diagnosis of NASH subsequent to commencing treatment;
                       commencing treatment;

                    -  Wash out for any of the anti-NASH therapies is as follows: under 10 days no
                       washout required, more than 10 days and up to 3 months treatment requires 6
                       weeks washout. Any treatment of over 3 months would require to re-biopsy to
                       ensure histological eligibility

               -  thiazolidinediones (glitazones), dipeptidyl peptidase 4 inhibitors (gliptins) or
                  glucagon-like peptide-1 analogs in the last 6 months. If treatment commenced and
                  is stable for more than 6 month prior to the determinant biopsy and the dose is
                  still stable at time of study entry, subjects will be eligible for recruitment.

               -  Allowable anti-diabetic treatment includes metformin and/or sulfonylureas
                  administered at constant dose for at least 2 months prior to study entry.

               -  Subjects treated with Insulin are eligible if clinically stable on insulin
                  treatment (i.e. no recurrent acute hypo-/hyperglycemic episodes diagnosed
                  clinically and by Glucose serum levels of &lt;50 mg/dL and &gt;200 mg/dL respectively)
                  for at least 2 months prior to study entry.

               -  immune modulatory agents including

                    -  In the last 3 months:

                    -  systemic steroids for more than 7 days.

                    -  daily treatment with multiple non-steroidal anti-inflammatory drugs (such as
                       aspirin &gt;100mg/day, ibuprofen, naproxen, meloxicam, celecoxib) for more than
                       1 month within 3 months prior to study entry;

                    -  In the last 12 months:

                    -  azathioprine, 6-mercaptopurine, methotrexate, cyclosporin, anti-TNFa
                       therapies (infliximab, adalimumab, etanercept) or anti-integrin therapies
                       (namixilab) ;

               -  more than 10 consecutive days oral or parenteral antibiotics within 4 weeks prior
                  to study entry (Note: such subjects would not be included in the stool and PBMC
                  analysis).

               -  variable dose of antilipidemic agents (3-hydroxy-3-methyl-glutaryl (HMG)-Co-A
                  reductase inhibitors - "statins") in the 3 months prior to study entry.

         15. The following laboratory abnormalities:

               -  Neutrophil count =1.0 x 10^9/L

               -  Platelets &lt;100 x 10^9/L

               -  Hemoglobin &lt;10 g/dL

               -  Albumin &lt;3.5 g/dL

               -  International Normalized Ratio (INR) &gt;1.5

               -  Total bilirubin &gt;1.5 x upper limit of reference range (unless Gilbert's syndrome
                  or extrahepatic source as denoted by increased indirect bilirubin fraction)

               -  Either creatinine clearance =60 mL/minute calculated by Cockroft Gault or
                  creatinine &gt;1.5x upper limit of reference range.

         16. Known substance abuse, including inhaled or injected drugs in the year prior to
             Screening.

         17. Cow milk allergy, lactose intolerance or any known or suspected hypersensitivity to
             study products.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>130</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>The Nepean Hospital - Penrith</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>The Alfred Hospital - Prahran</hospital>
    <postcode>2750 - Penrith</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>3004 - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Immuron Ltd.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the safety and preliminary efficacy of two dose levels of IMM-124E
      in reducing liver fat and/or serum alanine aminotransaminase (ALT) compared with placebo.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02316717</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dan Peres</name>
      <address>Immuron Ltd.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>